

1 **The SARS-CoV-2 conserved macrodomain is a highly efficient ADP-ribosylhydrolase**
2 **enzyme**

3
4 Yousef M.O. Alhammad¹, Maithri M. Kashipathy², Anuradha Roy³, David K. Johnson⁴, Peter
5 McDonald³, Kevin P. Battaile⁶, Philip Gao⁴, Scott Lovell² and Anthony R. Fehr^{1,*}

6 ¹Department of Molecular Biosciences, University of Kansas, Lawrence, Kansas 66045, USA

7 ²Protein Structure Laboratory, University of Kansas, Lawrence, Kansas 66047, USA

8 ³High Throughput Screening Laboratory, University of Kansas, Lawrence, Kansas 66047, USA

9 ⁴Molecular Graphics and Modeling Laboratory and the Computational Chemical Biology Core,
10 University of Kansas, Lawrence, Kansas 66047, USA

11 ⁵Protein Production Group, University of Kansas, Lawrence, Kansas 66047, USA

12 ⁶NYX, New York Structural Biology Center, Upton, NY 11973, USA

13

14

15 *Correspondence: arfehr@ku.edu; Tel.: +1- (785) 864-6626 (K.S.)

16

17

18 Running title: SARS-CoV-2 Mac1 removes ADP-ribose from protein *in vitro*

19

20 Keywords: Coronavirus, SARS-CoV-2, macrodomain, ADP-ribose

21 **ABSTRACT**

22 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other SARS-like-CoVs
23 encode 3 tandem macrodomains within non-structural protein 3 (nsp3). The first of these
24 macrodomains, termed Mac1, is conserved throughout CoVs, binds to mono- and poly-ADP-
25 ribose, and hydrolyzes mono-ADP-ribose (MAR) from target proteins. Mac1 is essential for
26 pathogenesis in multiple animal models of CoV infection, implicating this domain as a
27 prominent virulence factor and potential therapeutic target. Mac1 likely counters host-mediated
28 antiviral ADP-ribosylation, a posttranslational modification that is part of the host response to
29 viral infections. Here we report the crystal structure of SARS-CoV-2 Mac1 in complex with
30 ADP-ribose refined at 2.2 Å resolution. SARS-CoV-2, SARS-CoV and MERS-CoV Mac1
31 exhibit similar structural folds and ADP-ribose binding modes as shown by structural
32 comparison. All three CoV Mac1 proteins bound to ADP-ribose with low μM affinities. They
33 also demonstrated highly efficient de-MARylating activity, which was greater than that of the
34 human Mdo2 macrodomain. We conclude that the SARS-CoV-2 and other CoV Mac1 proteins
35 are highly efficient ADP-ribosylhydrolases with strikingly similar activity, indicating that
36 compounds targeting CoV Mac1 proteins may have broad antiviral activity against CoVs.
37

38 **IMPORTANCE**

39 SARS-CoV-2 has recently emerged into the human population and has led to a worldwide
40 pandemic of COVID-19 that has caused nearly 300K deaths worldwide. With, no currently
41 approved treatments, novel therapeutic strategies are desperately needed. All coronaviruses
42 encode for a highly conserved macrodomain (Mac1) that binds to and removes ADP-ribose, a
43 post-translation modification, from proteins. This protein domain is essential for CoV
44 pathogenesis and may be a novel therapeutic target. Thus, understanding its biochemistry and
45 enzyme activity are critical first steps for these efforts. Here we report the crystal structure of
46 SARS-CoV-2 Mac1 in complex with ADP-ribose, and describe its ADP-ribose binding and
47 hydrolysis activities in direct comparison to SARS-CoV and MERS-CoV Mac1 proteins, and a
48 human macrodomain. These results are an important first step for the design and testing of
49 potential therapies targeting this unique protein domain.

50 INTRODUCTION

51 The recently emerged pandemic outbreak of COVID-19 is caused by a novel coronavirus
52 named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)^{1,2}. As of May 11, 2020
53 this virus is responsible for ~ 4 million cases of COVID-19 and >285,000 deaths worldwide.
54 SARS-CoV-2 is a member of the lineage B β -CoVs with overall high sequence similarity with
55 other SARS-like CoVs, including SARS-CoV. While most of the genome is >80% similar with
56 SARS-CoV, there are regions where amino acid conservation is significantly lower. As expected,
57 the most divergent proteins in the SARS-CoV-2 genome from SARS-CoV include the Spike
58 glycoprotein and several accessory proteins including 8a (absent), 8b (extended), and 3b
59 (truncated). However, somewhat unexpectedly, several non-structural proteins also show
60 significant divergence from SARS-CoV, including non-structural proteins 3, 4, and 7, which
61 could affect the biology of SARS-CoV-2^{3,4}.

62 Coronaviruses encode 16 non-structural proteins that are translated from two open
63 reading frames (ORFs), replicase 1a and 1ab (rep1a and rep1ab)⁵. The largest non-structural
64 protein is non-structural protein 3 (nsp3) that encodes for multiple modular protein domains.
65 These domains in SARS-CoV-2 diverge in amino acid sequence from SARS-CoV as much as
66 30%, and it includes a large insertion of 25-41 residues just upstream of the first of three tandem
67 macrodomains (Mac1, Mac2, and Mac3) (Fig. 1A)³. In addition to this insertion, the individual
68 macrodomains show large amounts of amino acid divergence. Mac1 diverges 28% from SARS-
69 CoV and 59% from MERS-CoV, while Mac2 and Mac3 diverge 24% from SARS-CoV. It is
70 feasible that these significant sequence differences could impact the unique biology of SARS-
71 CoV-2. However, macrodomains have a highly conserved structure, and thus sequence
72 divergence may have little impact on their overall function. Mac1 is present in all CoVs, unlike

73 Mac2 and Mac3, and early structural and biochemical data demonstrated that it contains a
74 conserved three-layered $\alpha/\beta/\alpha$ fold and binds to ADP-ribose, poly-ADP-ribose, and other related
75 molecules⁶⁻¹⁰. ADP-ribose is buried in a hydrophobic cleft where the ADP-ribose binds to
76 several highly-conserved residues such as aspartic acid at position 23 (D23) and asparagine at
77 position 41 (N41) of SARS-CoV⁶. Mac1 homologs are also found in alphaviruses, Hepatitis E
78 virus, and Rubella virus, and structural analysis of these macrodomains have demonstrated that
79 they are very similar to CoV Mac1^{11,12} and are all members of the larger MacroD-type
80 macrodomain family, which includes human macrodomains Mdo1 and Mdo2¹³.

81 The CoV Mac1 was originally called an ADP-ribose-1''-phosphatase (ADRP) based on
82 data demonstrating that it could remove the phosphate group from ADP-ribose-1''-phosphate⁶⁻⁸.
83 However, the activity was rather modest, and it was unclear why this would impact a virus
84 infection. More recently it has been demonstrated that CoV Mac1 can hydrolyze the bond
85 between amino acid chains and ADP-ribose molecules¹⁴⁻¹⁶, indicating that it can reverse protein
86 ADP-ribosylation^{6,8}. ADP-ribosylation is a post-translational modification catalyzed by ADP-
87 ribosyltransferases (also known as PARPs) through transferring an ADP-ribose moiety from
88 NAD^+ onto target proteins¹⁷. The ADP-ribose is transferred as single mono-ADP-ribose unit
89 (MAR), or single units of ADP-ribose are transferred consecutively to form a poly-ADP-ribose
90 chain (PAR). CoV Mac1 efficiently hydrolyzes MAR, but has minimal activity against PAR^{14,15}.
91 Several MARylating PARPs are induced by interferon (IFN) and are known to inhibit virus
92 replication, implicating ADP-ribosylation in the host-response to infection¹⁸.

93 Several reports have addressed the role of Mac1 on the replication and pathogenesis of
94 CoVs, mostly using the mutation of a highly conserved asparagine to alanine. This mutation
95 abolished the ADP-ribosylhydrolase activity of SARS-CoV Mac1¹⁶. This mutation has minimal

96 effects on virus replication in transformed cells, but reduces viral load, leads to enhanced IFN
97 production, and strongly attenuates both Murine Hepatitis Virus (MHV) and SARS-CoV in
98 mouse models of infection^{7,16,19,20}. MHV Mac1 was also required for efficient replication in
99 primary macrophages, which could be partially rescued by PARP inhibitors or siRNA
100 knockdown of PARP12 or PARP14²¹. These data suggest that Mac1's likely function is to
101 counter PARP-mediated anti-viral ADP-ribosylation²². Mutations in the alphavirus and HEV
102 macrodomain are also known to have substantial phenotypic effects on virus replication and
103 pathogenesis^{14,23-26}. As viral macrodomains are clearly important virulence factors, they are
104 considered to be potential targets for anti-viral therapeutics²².

105 Based on the close structural and functional similarities between viral macrodomains we
106 hypothesized that SARS-CoV-2 Mac1 has similar binding and hydrolysis activity as other CoV
107 Mac1 enzymes. In this study, we determined the crystal structure of the SARS-CoV-2 Mac1
108 protein bound to ADP-ribose. Binding to ADP-ribose was further confirmed and directly
109 compared to a human macrodomain (Mdo2) and the SARS-CoV and MERS-CoV Mac1 proteins
110 by several *in vitro* assays. Finally, using an auto-modified protein substrate, we demonstrated
111 that SARS-CoV-2, SARS-CoV, and MERS-CoV Mac1 proteins are very efficient ADP-
112 ribosylhydrolases. These results will be instrumental in the design and testing of novel
113 therapeutic agents targeting the CoV Mac1 protein domain.

114 **RESULTS**

115 **Structure of the SARS-CoV-2 Mac1 complexed with ADP-ribose.** To create recombinant
116 SARS-CoV-2 Mac1 for structure determination and enzyme assays, nucleotides 3348-3872 of
117 SARS-CoV-2 isolate Wuhan-hu-1, representing amino acids I1023-K1197 of rep1a, were cloned
118 into a bacterial expression vector containing an N-terminal His tag and TEV cleavage site. We
119 obtained large amounts (>100 mg) of highly purified recombinant protein (Fig. S1A). A small
120 amount of this protein was digested by the TEV protease to obtain protein devoid of any extra
121 tags for crystallization and used to obtain crystals from which the structure was determined (Fig.
122 S1B). Our crystallization experiments resulted in the same crystal form (needle clusters) from
123 several conditions, but only when ADP-ribose was added to the protein. This represents an
124 additional crystal form ($P2_1$) amongst the recently determined SARS-CoV-2 macrodomain
125 structures²⁷⁻²⁹.

126 The structure of SARS-CoV-2 Mac1 complexed with ADP-ribose was obtained using X-
127 ray diffraction data to 2.2 Å resolution and contained four molecules in the asymmetric unit that
128 were nearly identical. The polypeptide chains could be traced from V3-M171 for subunits A/C
129 and V3-K172 for subunits B/D. Superposition of subunits B-D onto subunit A (169 residues
130 aligned) yielded RMSD deviations of 0.17 Å, 0.17 Å and 0.18 Å respectively between $C\alpha$ atoms.
131 As such, subunit A was used for the majority of the structure analysis described herein. The
132 SARS-CoV-2 Mac1 protein adopted a fold consistent with the MacroD subfamily of
133 macrodomains that contains a core composed of a mixed arrangement of 7 β -sheets (parallel and
134 antiparallel) that are flanked by 6 α -helices (Fig. 2A-B).

135 As mentioned above, apo crystals were never observed for our construct, though the apo
136 structure has been solved by researchers at The Center for Structural Genomics of Infectious

137 Diseases (PDB 6WEN)²⁸ and University of Wisconsin-Milwaukee (PDB 6WEY)²⁷. Further
138 analysis of the amino acid sequences used for expression and purification revealed that our
139 construct had 5 additional residues at the C-terminus (MKSEK) and differs slightly at the N-
140 terminus as well (GIE vs GE) relative to 6WEN. In addition, the sequence used to obtain the
141 structure of 6WEY is slightly shorter than SARS-CoV-2 Mac1 at both the N and C-terminal
142 regions (Fig. S2A). To assess the effect of these additional residues on crystallization, chain B
143 of the SARS-CoV-2 Mac1, which was traced to residue K172, was superimposed onto subunit A
144 of PDB 6W02²⁹, a previously determined structure of ADP-ribose bound SARS-CoV-2 Mac1.
145 Analysis of the crystal packing of 6W02 indicates that the additional residues at the C-terminus
146 would clash with symmetry related molecules (Fig. S2B). This suggests that the presence of
147 these extra residues at the C-terminus likely prevented the generation of the more tightly packed
148 crystal forms obtained for 6W02 and 6WEY, which diffracted to high resolution.

149 The ADP-ribose binding pocket contained large regions of positive electron density
150 consistent with ADP-ribose molecules (Fig. 3A). The adenine forms two hydrogen bonds with
151 D22-I23, which makes up a small loop between β 2 and the N-terminal half of α 1. The side chain
152 of D22 interacts with N6, while the backbone nitrogen atom of I23 interacts with N1, in a very
153 similar fashion to the SARS-CoV macrodomain⁶. A large number of contacts are made in the
154 loop between β 3 and α 2 which includes many highly-conserved residues, including a GGG
155 (motif) and N40, which is completely conserved in all enzymatically active macrodomains³⁰.
156 N40 is positioned to make hydrogen bonds with the 3' OH groups of the distal ribose, as well as
157 a conserved water molecule. K44 and G46 also make hydrogen bonds with the 2' OH of the
158 distal ribose, G48 makes contact with the 1' OH and a water that resides near the catalytic site,
159 while the backbone nitrogen atom of V49 hydrogen bonds with the α -phosphate. The other major

160 interactions with ADP-ribose occur in residues G130, I131, and F132 that are in the loop
161 between $\beta 6$ and $\alpha 5$ (Fig. 3B). The α -phosphate accepts a hydrogen bond from the nitrogen atom
162 of I131, while the β -phosphate accepts hydrogen bonds from the backbone nitrogen atom of
163 G130 and F132. Loops $\beta 3$ - $\alpha 2$ and $\beta 6$ - $\alpha 5$ are connected by an isoleucine bridge that forms a
164 narrow channel around the diphosphate which helps position the terminal ribose for water-
165 mediated catalysis⁶. Additionally, a network of direct contacts of ADP-ribose to solvent along
166 with water mediated contacts to the protein are shown (Fig. 3C).

167 **Comparison of SARS-CoV-2 with other CoV macrodomain structures.** We next
168 sought to compare the SARS-CoV-2 Mac1 to other deposited structures of this protein.
169 Superposition with Apo (6WEN) and ADP-ribose complexed protein (6W02) yielded RMSD of
170 0.48 Å (168 residues) and 0.37 Å (165 residues), respectively, indicating a high degree of
171 similarity (Fig. S3A-B). Comparison of the ADP-ribose binding site of SARS-CoV-2 Mac1 with
172 that of the apo structure (6WEN) revealed minor conformational differences in order to
173 accommodate ADP-ribose binding. The loop between $\beta 3$ and $\alpha 2$ (H45-V49) undergoes a change
174 in conformation and the sidechain of F132 is moved out of the ADP-ribose binding site (Fig.
175 S3C). Our ADP-ribose bound structure is nearly identical to 6W02, except for slight deviations
176 in the $\beta 3$ - $\alpha 2$ loop and an altered conformation of F156, where the aryl ring of F156 is moved
177 closer to the adenine ring (Fig. S3 C-D). However, this is likely a result of crystal packing as
178 F156 adopts this conformation in each subunit and would likely clash with subunit residues
179 related by either crystallographic or non-crystallographic symmetry.

180 We next compared the ADP-ribose bound SARS-CoV-2 Mac1 structure with that of
181 SARS-CoV (PDB 2FAV) and MERS-CoV (PDB 5HOL) Mac1 proteins. Superposition yielded
182 RMSD deviations of 0.71 Å (166 residues) and 1.06 Å (161 residues) for 2FAV and 5HOL,

183 respectively. Additionally, the ADP-ribose binding mode in the SARS-CoV and SARS-CoV-2
184 structures almost perfectly superimposed (Fig. 4 A-D). The conserved aspartic acid residue
185 (D22, SARS-CoV-2) that binds to adenine, are localized in a similar region although there are
186 slight differences in the rotamers about the C β -C γ bond. The angles between the mean planes
187 defined by the OD1, CG and OD2 atoms relative to SARS-CoV-2 Mac1 is 23.1° and 46.5° for
188 the SARS-CoV and MERS-CoV Mac1 structures, respectively. Another notable difference is
189 that SARS-CoV and SARS-CoV-2 macrodomains have an isoleucine (I23) following this
190 aspartic acid while MERS-CoV has an alanine (A22). Conversely, SARS-CoV-2 and SARS-
191 CoV Mac1 have a valine instead of an isoleucine immediately following the GGG motif
192 (V49/I48). From these structures it appears that having two isoleucines in this location would
193 clash, and that lineage B and lineage C β -CoVs has evolved in unique ways to create space in
194 this pocket (Fig. 4D and data not shown). Despite these small differences in local structure, the
195 overall structure of CoV Mac1 domains remain remarkably conserved, and indicates they likely
196 have similar biochemical activities and biological functions.

197 **SARS-CoV, SARS-CoV-2, and MERS-CoV bind to ADP-ribose with similar**
198 **affinities.** To determine if the CoV macrodomains had any noticeable differences in their ability
199 to bind ADP-ribose, we performed isothermal titration calorimetry (ITC), which measures the
200 energy released or absorbed during a binding reaction. Macrodomein proteins from human
201 (Mdo2), SARS-CoV, MERS-CoV, and SARS-CoV-2 were purified (Fig. S1A) and tested for
202 their affinity to ADP-ribose. All CoV Mac1 proteins bound to ADP-ribose with low micromolar
203 affinity (7-16 μ M), while human Mdo2 bound with an affinity about 10-times stronger (~220
204 nM) (Fig. 5A-B). As a control we tested the ability of the MERS-CoV macrodomain to bind to
205 ATP, and only observed minimal binding with mM affinity (data not shown). At higher

206 concentrations, the SARS-CoV-2 macrodomain caused a slightly endothermic reaction,
207 potentially the result of protein aggregation or a change in conformation (Fig. 5A). The MERS-
208 CoV Mac1 had a greater affinity for ADP-ribose than SARS-CoV or SARS-CoV-2 Mac1 in the
209 ITC assay (Fig. 5A-B), however, our results found the differences between these macrodomain
210 proteins to be much closer than previously reported⁹. As an alternate method to confirm ADP-
211 ribose binding, we conducted a thermal shift assay. All 4 macrodomains tested denatured at
212 higher temperatures with the addition of ADP-ribose (Fig. 5C). We conclude that lineage B and
213 lineage C β -CoV Mac1 proteins bind to ADP-ribose with similar affinities.

214 **CoV macrodomains are highly efficient mono-ADP-ribosylhydrolases.** To examine
215 the ADP-ribosylhydrolase activity of coronaviruses Mac1, we first tested the viability of using
216 antibodies to detect mono-ADP-ribosylated protein. Previously, only radiolabeled NAD⁺ has
217 been used to label ADP-ribosylated protein^{14,15}. To create a mono-ADP-ribosylated substrate, the
218 catalytic domain of the PARP10 (GST-PARP10 CD) protein was incubated with NAD⁺, leading
219 to its auto-ADP-ribosylation. We then tested a panel of monoclonal antibodies that detect mono-
220 ADP-ribose (MAR), poly-ADP-ribose (PAR), or both MAR and PAR for the ability to detect
221 MARylated PARP10. The anti-MAR and anti-MAR/PAR antibodies, but not anti-PAR antibody,
222 bound to MARylated PARP10 (Fig. S4). From herein we utilized the anti-MAR antibody to
223 detect ADP-ribosylated PARP10.

224 We next tested the ability of SARS-CoV-2 Mac1 to remove ADP-ribose from
225 MARylated PARP10. SARS-CoV-2 Mac1 and MARylated PARP10 were incubated at
226 equimolar amounts of protein at 37 °C and the reaction was stopped at 5, 10, 20, 30, 45 or 60
227 minutes (Fig. 6A). As a control, MARylated PARP10 was incubated alone for 60 minutes at
228 37°C. Each reaction had equivalent amounts of MARylated PARP10 and Mac1 which was

229 confirmed by Coomassie Blue staining (Fig. 6A). An immediate reduction of more than 50%
230 band intensity was observed within five minutes, and the ADP-ribose modification was nearly
231 completely removed by SARS-CoV-2 Mac1 within 30 minutes (Fig. 6A). The MARylated
232 PAPR10 bands intensities were calculated, plotted, and fit to a non-linear regression curve (Fig.
233 6B). This result indicates that the SARS-CoV-2 Mac1 protein is a highly efficient ADP-
234 ribosylhydrolase.

235 Next, we compared ADP-ribosylhydrolase activity of Mac1 from SARS-CoV-2, SARS-
236 CoV, and MERS-CoV and human Mdo2. These proteins were incubated with MARylated
237 PARP10 as described above and the removal of MAR was analyzed at 5, 15 and 30 minutes (Fig.
238 6C). MAR was rapidly removed from MARylated PARP10 with the CoV Mac1 proteins (Fig.
239 6D). Approximately 95% of MAR was removed by SARS-CoV and SARS-CoV-2 Mac1 within
240 15 minutes, while at the same timepoint MERS-CoV Mac1 removed about 85% of MAR (Fig.
241 6D). A more gradual decrease of MARylated PARP10 band intensity was observed with Mdo2.
242 It removed approximately 70% of MAR in 30 minutes, which was significantly different from
243 both SARS-CoV and SARS-CoV-2 Mac1. These data showed that CoV Mac1 proteins have
244 similar ADP-ribosylhydrolase activity against an auto-modified PARP10 protein and have
245 increased activity when compared to the human Mdo2 protein for this substrate under these
246 conditions. However, further enzymatic analyses of these proteins are warranted to more
247 thoroughly understand their kinetics and affinities for ADP-ribosylated substrates.

248

249 **DISCUSSION**

250 Here we report the crystal structure of SARS-CoV-2 Mac1. It has a conserved three-
251 layered $\alpha/\beta/\alpha$ fold typical of the MacroD family of macrodomains, and is extremely similar to
252 other CoV Mac1 proteins (Fig. 2-4). The conserved coronavirus macrodomain (Mac1) was
253 initially described as an ADP-ribose-1''-phosphatase (ADRP), as it was shown to be structurally
254 similar to yeast enzymes that have this enzymatic activity³¹. Early biochemical studies confirmed
255 this activity for CoV Mac1, though its phosphatase activity for this substrate was rather modest⁶⁻
256 ⁸. Later, it was shown that mammalian macrodomain proteins could remove ADP-ribose from
257 protein substrates, indicating protein de-ADP-ribosylation as a more likely function for the viral
258 macrodomains^{30,32,33}. Shortly thereafter, the SARS-CoV, hCoV-229E, FIPV, several alphavirus,
259 and the hepatitis E virus macrodomains were demonstrated to have de-ADP-ribosylating activity
260 ¹⁴⁻¹⁶. However, this activity has not yet been reported for the MERS-CoV or SARS-CoV-2 Mac1
261 protein. In this study, we show that the Mac1 proteins from SARS-CoV, MERS-CoV and SARS-
262 CoV-2 hydrolyze ADP-ribose from a protein substrate (Fig. 6). Their activities were similar
263 despite sequence divergence of almost 60% between SARS-CoV-2 and MERS-CoV. We then
264 compared these activities to the human Mdo2 macrodomain. Mdo2 had a greater affinity for
265 ADP-ribose than the viral enzymes, but had significantly reduced enzyme activity in our
266 experiments. These results suggest that the human and viral enzymes have sufficient structural
267 differences that result in differences in biochemical activities. Finally, while all previous studies
268 of macrodomain de-ADP-ribosylation had used radiolabeled substrate, we obtained highly
269 repeatable and robust data utilizing antibodies designed to specifically recognized mono-ADP-
270 ribose³⁴. The use of these antibodies should enhance the feasibility of this assay for many labs
271 that are not equipped for radioactive work.

272 The functional importance of Mac1 has been demonstrated in several reports, mostly
273 utilizing the mutation of a highly conserved asparagine that mediates contact with the distal
274 ribose (Fig. 3B)^{16,19,20}. From these reports it is clear that CoV Mac1 is vital for the ability of
275 these viruses to cause disease, and have indicated that it could be a novel therapeutic target.
276 Despite this, there are no known compounds that inhibit this domain. The outbreak of COVID-19
277 has illustrated an incredible need for developing multiple therapeutic drugs targeting conserved
278 coronavirus proteins. Mac1 appears to be an ideal candidate for further drug development based
279 on its: *i*) highly conserved structure and biochemical activities within CoVs; and *ii*) its clear
280 importance for multiple CoVs to cause disease. Targeting Mac1 may also have the benefit of
281 enhancing the innate immune response, as we have shown that Mac1 is required for some CoVs
282 to block IFN production^{16,21}. Considering that Mac1 from divergent α CoVs such as 229E and
283 FIPV also have de-ADP-ribosylating activity^{14,15}, it is also possible that compounds targeting
284 Mac1 could prevent disease caused by of wide variety of CoV, including those of veterinary
285 importance like porcine epidemic diarrhea virus (PEDV). Further, compounds that inhibit Mac1
286 could help identify its protein targets during infection. Future studies could utilize the SARS-
287 CoV-2 Mac1 structure to identify the mechanisms it uses to bind to its biologically relevant
288 protein substrates, remove ADP-ribose from these proteins, and potentially define the precise
289 function for Mac1 in CoV replication and pathogenesis. These studies will be critical for the
290 design and development of highly-specific Mac1 inhibitors that could be used therapeutically to
291 mitigate COVID-19 or future CoV outbreaks.

292 **METHODS**

293 **Plasmids**

294 The SARS-CoV macrodomain (Mac1) (residues 1000-1172 of pp1a) was cloned into the
295 pET21a+ expression vector with an N-terminal His tag. The MERS-CoV Mac1 (residues 1110-
296 1273 of pp1a) was also cloned into pET21a+ with a C-terminal His tag. SARS-CoV-2 Mac1
297 (residues 1023-1197 of pp1a) was cloned into the pET30a+ expression vector with an N-terminal
298 His tag and a TEV cleavage site (Synbio). The pETM-CN Mdo2 Mac1 (residues 7-243)
299 expression vector with an N-terminal His-TEV-V5 tag and the pGEX4T-PARP10CD (residues
300 818-1025) expression vector with an N-terminal GST tag were previously described³⁰ (Ivan
301 Ahel, Oxford University). All plasmids were confirmed by restriction digest, PCR, and direct
302 sequencing.

303 **Protein Expression and Purification**

304 A single colony of *E. coli* cells (C41(DE3)) containing plasmids harboring the constructs
305 of the macrodomain proteins was inoculated into 10mL LB media and grown overnight at 37°C
306 with shaking at 250 rpm. The overnight culture was transferred to a shaker flask containing 2X
307 1L TB media at 37°C until the OD600 reached to about 0.7. The proteins were either induced
308 with 0.4 mM IPTG at 37°C for 3 hours, or 17°C for 20 hours. Cells were pelleted at 3500 × g for
309 10 min and frozen at -80°C. Frozen cells were thawed at room temperature, resuspended in
310 50mM tris (pH 7.6), 150mM NaCl, and sonicated using the following cycle parameters:
311 Amplitude: 50%, Pulse length: 30 seconds, Number of pulses: 12, while incubating on ice for
312 >1min between pulses. The soluble fraction was obtained by centrifuging the cell lysate at
313 45,450 × g for 30 minutes at 4°C. The expressed soluble proteins were purified by affinity
314 chromatography using a 5 ml prepacked HisTrap HP column on an AKTA Pure protein

315 purification system (GE Healthcare). The fractions were further purified by size-exclusion
316 chromatography (SEC) with a Superdex 75 10/300 GL column equilibrated with 20mM Tris (pH
317 8.0), 150 mM NaCl and the protein sized as a monomer relative to the column calibration
318 standards. To cleave off the His tag from the SARS-CoV-2 Mac1, purified TEV protease was
319 added to purified SARS-CoV-2 Mac1 protein at a ratio of 1:10 (w/w), and then passed back
320 through the Ni-NTA HP column. Protein was collected in the flow through and equilibrated with
321 20mM Tris (pH 8.0), 150 mM NaCl. The SARS-CoV-2 Mac1, free from the N-terminal His tag,
322 was used for subsequent crystallization experiments.

323 For the PARP 10 protein, the cell pellet was resuspended in in 50mM Tris-HCl (pH 8.0),
324 500mM NaCl, 0.1mM EDTA, 25% glycerol, 1mM DTT and sonicated as described above. The
325 cell lysate was incubated with 10 ml of Glutathione Sepharose 4B resin from GE Healthcare,
326 equilibrated with the same buffer for 2 hours, then applied to a gravity flow column to allow
327 unbound proteins to flow through. The column was washed with the resuspension buffer till the
328 absorbance at 280 nm reached baseline. The bound protein was eluted out of the column with
329 resuspension buffer containing 20mM reduced glutathione and then dialyzed back into the
330 resuspension buffer overnight at 4°C.

331 **Isothermal Titration Calorimetry**

332 All ITC titrations were performed on a MicroCal PEAQ-ITC instrument (Malvern
333 Pananalytical Inc., MA). All reactions were performed in 20 mM Tris pH 7.5, 150 mM NaCl
334 using 100 uM of all macrodomain proteins at 25°C. Titration of 2 mM ADP-ribose or ATP
335 (MilliporeSigma) contained in the stirring syringe included a single 0.4 μ L injection, followed by
336 18 consecutive injections of 2 μ L. Data analysis of thermograms was analyzed using one set of

337 binding sites model of the MicroCal ITC software to obtain all fitting model parameters for the
338 experiments.

339 **Differential Scanning Fluorimetry (DSF)**

340 Thermal shift assay with DSF involved use of LightCycler® 480 Instrument (Roche
341 Diagnostics). In total, a 15µl mixture containing 8X SYPRO Orange (Invitrogen), and 10 µM
342 Mac1 protein in buffer containing 20 mM Hepes, NaOH, pH 7.5 and various concentrations of
343 ADP-ribose were mixed on ice in 384-well PCR plate (Roche). Fluorescent signals were
344 measured from 25 to 95 °C in 0.2 °C/30-s steps (excitation, 470–505 nm; detection, 540–700
345 nm). The main measurements were carried out in triplicate. Data evaluation and T_m
346 determination involved use of the Roche LightCycler® 480 Protein Melting Analysis software,
347 and data fitting calculations involved the use of single site binding curve analysis on Graphpad
348 Prism.

349 **DeMARylation Assay**

350 *Automodification of PARP10 protein:* A 10 µM solution of purified PAPR10 protein was
351 incubated for 20 minutes at 37°C with 1mM final concentration of β-Nicotinamide adenine
352 dinucleotide (β NAD⁺) (Millipore-Sigma) in a reaction buffer (50mM HEPES, 150mM NaCl,
353 0.2MM DTT, and 0.02% NP-40). MARylated PARP10 was aliquoted and stored at -80°C.

354 *PAPR10 ADP-ribose hydrolysis:* All reactions were performed at 37°C for the designated
355 time. One µmol of MARylated PARP10 and purified Mac1 protein was added in the reaction
356 buffer (50mM HEPES, 150mM NaCl, 0.2MM DTT, and 0.02% NP-40). The reaction was
357 stopped with addition of 2X Laemmli sample buffer containing 10% β-mercapto-ethanol.

358

359 **Immunoblotting**

360 Protein samples were heated at 95°C for 5 minutes before loading onto SDS-PAGE. The
361 proteins were separated on SDS-PAGE cassette (Thermo Fisher Scientific Bolt™ 4-12% Bis-
362 Tris Plus Gels) in 1x MES running buffer. For direct protein detection, the SDS-PAGE was
363 stained using InstantBlue® Protein Stain (Expedeon). For immunoblotting, the separated
364 proteins were transferred onto polyvinylidene difluoride (PVDF) membrane using iBlot™ 2 Dry
365 Blotting System (ThermoFisher Scientific). The blot was blocked with 5% skim milk in PBS
366 containing 0.05% Tween-20 and probed with anti-mono or poly ADP-ribose binding antibodies
367 MABE1076 (α -MAR), MABC547 (α -PAR), MABE1075 (α -MAR/PAR) (Millipore-Sigma) and
368 anti-GST tag monoclonal antibody MA4-004 (ThermoFisher Scientific). The primary antibodies
369 were detected with secondary infrared anti-rabbit and anti-mouse antibodies (LI-COR
370 Biosciences). All immunoblots were visualized using Odyssey® CLx Imaging System (LI-COR
371 Biosciences).

372 **Structure Determination**

373 *Crystallization and Data Collection:* Purified SARS-CoV-2 Mac1 in 150mM NaCl,
374 20mM Tris pH 8.0 was concentrated to 13.8 mg/mL for crystallization screening. All
375 crystallization experiments were setup using an NT8 drop-setting robot (Formulatrix Inc.) and
376 UVXPO MRC (Molecular Dimensions) sitting drop vapor diffusion plates at 18°C. 100 nL of
377 protein and 100 nL crystallization solution were dispensed and equilibrated against 50 uL of the
378 latter. The SARS-CoV-2 Mac1 complex with ADP-ribose was prepared by adding the ligand,
379 from a 100 mM stock in water, to the protein at a final concentration of 2 mM. Crystals that were
380 obtained in 1-2 days from the Salt Rx HT screen (Hampton Research) condition E10 (1.8 M
381 NaH₂PO₄/K₂HPO₄, pH 8.2). Refinement screening was conducted using the additive screen HT

382 (Hampton Research) by supplementing 10% of each additive to the Salt Rx HT E10 condition in
383 a new 96-well UVXPO crystallization plate. The crystals used for data collection were obtained
384 from Salt Rx HT E10 supplemented with 0.1 M NDSB-256 from the additive screen (Fig. S1).
385 Samples were transferred to a fresh drop composed of 80% crystallization solution and 20%
386 (v/v) PEG 200 and stored in liquid nitrogen. X-ray diffraction data were collected at the
387 Advanced Photon Source, IMCA-CAT beamline 17-ID using a Dectris Eiger 2X 9M pixel array
388 detector.

389 *Structure Solution and Refinement:* Intensities were integrated using XDS^{35,36} via
390 Autoproc³⁷ and the Laue class analysis and data scaling were performed with Aimless³⁸.
391 Notably, a pseudo-translational symmetry peak was observed at (0, 0.31 0.5) that was 44.6% of
392 the origin. Structure solution was conducted by molecular replacement with Phaser³⁹ using a
393 previously determined structure of ADP-ribose bound SARS-CoV-2 Mac1 (PDB 6W02) as the
394 search model. The top solution was obtained in the space group $P2_1$ with four molecules in the
395 asymmetric unit. Structure refinement and manual model building were conducted with Phenix⁴⁰
396 and Coot⁴¹ respectively. Disordered side chains were truncated to the point for which electron
397 density could be observed. Structure validation was conducted with Molprobit⁴² and figures
398 were prepared using the CCP4MG package⁴³. Superposition of the macrodomain structures was
399 conducted with GESAMT⁴⁴.

400 **Statistical Analysis**

401 All statistical analyses were done using an unpaired two-tailed student's t-test to assess
402 differences in mean values between groups, and graphs are expressed as mean \pm SD. Significant p
403 values are denoted with * $p \leq 0.05$.

404 **ACCESSION CODES**

405 The coordinates and structure factors for SARS-CoV-2 Mac1 were deposited to the
406 Worldwide Protein Databank (wwPDB) with the accession code 6WOJ.

407 **ACKNOWLEDGEMENTS**

408 We'd like to thank Drs. Ivan Ahel and Gytis Jankevicius for providing protein expression
409 plasmids. This research was funded by the National Institutes of Health (NIH), grant numbers
410 P20 GM113117, P30GM110761, and AI134993-01 to A.R.F. Use of the IMCA-CAT beamline
411 17-ID at the Advanced Photon Source was supported by the companies of the Industrial
412 Macromolecular Crystallography Association through a contract with Hauptman-Woodward
413 Medical Research Institute. Use of the Advanced Photon Source was supported by the U.S.
414 Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No.
415 DE-AC02-06CH11357.

416 **REFERENCES**

- 417
- 418 1. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat
419 origin. *Nature* **579**, 270-273 (2020).
- 420 2. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The
421 species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV
422 and naming it SARS-CoV-2. *Nat Microbiol* **5**, 536-544 (2020).
- 423 3. Srinivasan, S. et al. Structural Genomics of SARS-CoV-2 Indicates Evolutionary
424 Conserved Functional Regions of Viral Proteins. *Viruses* **12**, 360 (2020).
- 425 4. Wu, C. et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential
426 drugs by computational methods. *Acta Pharm Sin B* (2020).
- 427 5. Fehr, A.R. & Perlman, S. Coronaviruses: An Overview of Their Replication and
428 Pathogenesis. in *Coronaviruses*, Vol. 1282 (eds. Maier, H.J., Bickerton, E. & Britton, P.)
429 1-23 (Springer New York, 2015).
- 430 6. Egloff, M.P. et al. Structural and functional basis for ADP-ribose and poly(ADP-ribose)
431 binding by viral macro domains. *J Virol* **80**, 8493-502 (2006).
- 432 7. Putics, A., Filipowicz, W., Hall, J., Gorbalenya, A.E. & Ziebuhr, J. ADP-ribose-1"-
433 monophosphatase: a conserved coronavirus enzyme that is dispensable for viral
434 replication in tissue culture. *J Virol* **79**, 12721-31 (2005).
- 435 8. Saikatendu, K.S. et al. Structural basis of severe acute respiratory syndrome coronavirus
436 ADP-ribose-1"-phosphate dephosphorylation by a conserved domain of nsP3. *Structure*
437 **13**, 1665-75 (2005).
- 438 9. Cho, C.C., Lin, M.H., Chuang, C.Y. & Hsu, C.H. Macro Domain from Middle East
439 Respiratory Syndrome Coronavirus (MERS-CoV) Is an Efficient ADP-ribose Binding
440 Module: CRYSTAL STRUCTURE AND BIOCHEMICAL STUDIES. *J Biol Chem* **291**,
441 4894-902 (2016).
- 442 10. Xu, Y. et al. Crystal structures of two coronavirus ADP-ribose-1"-monophosphatases and
443 their complexes with ADP-Ribose: a systematic structural analysis of the viral ADRP
444 domain. *J Virol* **83**, 1083-92 (2009).
- 445 11. Makrynitsa, G.I. et al. Conformational plasticity of the VEEV macro domain is important
446 for binding of ADP-ribose. *J Struct Biol* **206**, 119-127 (2019).
- 447 12. Malet, H. et al. The crystal structures of Chikungunya and Venezuelan equine
448 encephalitis virus nsP3 macro domains define a conserved adenosine binding pocket. *J*
449 *Virol* **83**, 6534-45 (2009).
- 450 13. Rack, J.G., Perina, D. & Ahel, I. Macrod domains: Structure, Function, Evolution, and
451 Catalytic Activities. *Annu Rev Biochem* **85**, 431-54 (2016).
- 452 14. Li, C. et al. Viral Macro Domains Reverse Protein ADP-Ribosylation. *J Virol* **90**, 8478-
453 86 (2016).
- 454 15. Ecke, L. et al. The conserved macrodomains of the non-structural proteins of
455 Chikungunya virus and other pathogenic positive strand RNA viruses function as mono-
456 ADP-ribosylhydrolases. *Sci Rep* **7**, 41746 (2017).
- 457 16. Fehr, A.R. et al. The Conserved Coronavirus Macrodomain Promotes Virulence and
458 Suppresses the Innate Immune Response during Severe Acute Respiratory Syndrome
459 Coronavirus Infection. *mBio* **7**, e01721-16 (2016).

- 460 17. Kim, D.S., Challa, S., Jones, A. & Kraus, W.L. PARPs and ADP-ribosylation in RNA
461 biology: from RNA expression and processing to protein translation and proteostasis.
462 *Genes Dev* **34**, 302-320 (2020).
- 463 18. Fehr, A.R. et al. The impact of PARPs and ADP-ribosylation on inflammation and host-
464 pathogen interactions. *Genes Dev* **34**, 341-359 (2020).
- 465 19. Eriksson, K.K., Cervantes-Barragan, L., Ludewig, B. & Thiel, V. Mouse hepatitis virus
466 liver pathology is dependent on ADP-ribose-1"-phosphatase, a viral function conserved in
467 the alpha-like supergroup. *J Virol* **82**, 12325-34 (2008).
- 468 20. Fehr, A.R. et al. The nsp3 macrodomain promotes virulence in mice with coronavirus-
469 induced encephalitis. *J Virol* **89**, 1523-36 (2015).
- 470 21. Grunewald, M.E. et al. The coronavirus macrodomain is required to prevent PARP-
471 mediated inhibition of virus replication and enhancement of IFN expression. *PLoS*
472 *Pathog* **15**, e1007756 (2019).
- 473 22. Alhammad, Y.M.O. & Fehr, A.R. The Viral Macrodomain Counters Host Antiviral ADP-
474 Ribosylation. *Viruses* **12**, 384 (2020).
- 475 23. Abraham, R. et al. ADP-ribosyl-binding and hydrolase activities of the alphavirus nsP3
476 macrodomain are critical for initiation of virus replication. *Proc Natl Acad Sci U S A* **115**,
477 E10457-E10466 (2018).
- 478 24. Abraham, R. et al. Both ADP-Ribosyl-Binding and Hydrolase Activities of the
479 Alphavirus nsP3 Macrodomain Affect Neurovirulence in Mice. *mBio* **11**(2020).
- 480 25. McPherson, R.L. et al. ADP-ribosylhydrolase activity of Chikungunya virus
481 macrodomain is critical for virus replication and virulence. *Proc Natl Acad Sci U S A*
482 **114**, 1666-1671 (2017).
- 483 26. Parvez, M.K. The hepatitis E virus ORF1 'X-domain' residues form a putative
484 macrodomain protein/Appr-1"-pase catalytic-site, critical for viral RNA replication. *Gene*
485 **566**, 47-53 (2015).
- 486 27. Vuksanovic, N., Silvaggi, N.R. National Science Foundation (NSF, United States). High-
487 resolution structure of the SARS-CoV-2 NSP3 Macro X domain doi:
488 10.2210/pdb6WEY/pdb. (2020).
- 489 28. Michalska, K., Stols, L., Jedrzejczak, R., Endres, M., Babnigg, G., Kim, Y., Joachimiak,
490 A., Center for Structural Genomics of Infectious Diseases (CSGID). Crystal Structure of
491 ADP ribose phosphatase of NSP3 from SARS-CoV-2 in the apo doi:
492 10.2210/pdb6WEN/pdb. (2020).
- 493 29. Michalska, K., Kim, Y., Jedrzejczak, R., Maltseva, N., Endres, M., Mececar, A.,
494 Joachimiak, A., Center for Structural Genomics of Infectious Diseases (CSGID). Crystal
495 Structure of ADP ribose phosphatase of NSP3 from SARS CoV-2 in the complex with
496 ADP ribose doi: 10.2210/pdb6W02/pdb. (2020).
- 497 30. Jankevicius, G. et al. A family of macrodomain proteins reverses cellular mono-ADP-
498 ribosylation. *Nat Struct Mol Biol* **20**, 508-14 (2013).
- 499 31. Shull, N.P., Spinelli, S.L. & Phizicky, E.M. A highly specific phosphatase that acts on
500 ADP-ribose 1"-phosphate, a metabolite of tRNA splicing in *Saccharomyces cerevisiae*.
501 *Nucleic Acids Res* **33**, 650-60 (2005).
- 502 32. Rosenthal, F. et al. Macrodomain-containing proteins are new mono-ADP-
503 ribosylhydrolases. *Nat Struct Mol Biol* **20**, 502-7 (2013).
- 504 33. Sharifi, R. et al. Deficiency of terminal ADP-ribose protein glycohydrolase
505 TARG1/C6orf130 in neurodegenerative disease. *EMBO J* **32**, 1225-37 (2013).

- 506 34. Gibson, B.A., Conrad, L.B., Huang, D. & Kraus, W.L. Generation and Characterization
507 of Recombinant Antibody-like ADP-Ribose Binding Proteins. *Biochemistry* **56**, 6305-
508 6316 (2017).
- 509 35. Kabsch, W. Evaluation of single-crystal X-ray diffraction data from a position-sensitive
510 detector. *Journal of Applied Crystallography* **21**, 916-924 (1988).
- 511 36. Kabsch, W. Xds. *Acta Crystallogr D Biol Crystallogr* **66**, 125-32 (2010).
- 512 37. Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. *Acta*
513 *Crystallogr D Biol Crystallogr* **67**, 293-302 (2011).
- 514 38. Evans, P.R. An introduction to data reduction: space-group determination, scaling and
515 intensity statistics. *Acta Crystallogr D Biol Crystallogr* **67**, 282-92 (2011).
- 516 39. McCoy, A.J. et al. Phaser crystallographic software. *J Appl Crystallogr* **40**, 658-674
517 (2007).
- 518 40. Adams, P.D. et al. PHENIX: a comprehensive Python-based system for macromolecular
519 structure solution. *Acta Crystallogr D Biol Crystallogr* **66**, 213-21 (2010).
- 520 41. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot.
521 *Acta Crystallogr D Biol Crystallogr* **66**, 486-501 (2010).
- 522 42. Chen, V.B. et al. MolProbity: all-atom structure validation for macromolecular
523 crystallography. *Acta Crystallogr D Biol Crystallogr* **66**, 12-21 (2010).
- 524 43. Potterton, L. et al. Developments in the CCP4 molecular-graphics project. *Acta*
525 *Crystallogr D Biol Crystallogr* **60**, 2288-94 (2004).
- 526 44. Krissinel, E. Enhanced fold recognition using efficient short fragment clustering. *Journal*
527 *of molecular biochemistry* **1**, 76 (2012).
- 528 45. Evans, P. Scaling and assessment of data quality. *Acta Crystallogr D Biol Crystallogr* **62**,
529 72-82 (2006).
- 530 46. Diederichs, K. & Karplus, P.A. Improved R-factors for diffraction data analysis in
531 macromolecular crystallography. *Nat Struct Biol* **4**, 269-75 (1997).
- 532 47. Weiss, M.S. Global indicators of X-ray data quality. *Journal of Applied Crystallography*
533 **34**, 130-135 (2001).
- 534 48. Evans, P. Resolving Some Old Problems in Protein Crystallography. *Science* **336**, 986-
535 987 (2012).
- 536 49. Karplus, P.A. & Diederichs, K. Linking crystallographic model and data quality. *Science*
537 **336**, 1030-3 (2012).
- 538
- 539

540 **Table 1.** Crystallographic data for SARS-CoV-2 Mac1.
541

SARS-CoV-2 Mac1	
Data Collection	
Unit-cell parameters (Å, °)	$a=59.72, b=83.17,$ $c=84.24, \beta=94.4$
Space group	$P2_1$
Resolution (Å) ¹	48.41-2.20 (2.27-2.20)
Wavelength (Å)	1.0000
Temperature (K)	100
Observed reflections	144,767
Unique reflections	41,586
$\langle I/\sigma(I) \rangle$ ¹	7.3 (1.9)
Completeness (%) ¹	99.4 (99.7)
Multiplicity ¹	3.5 (3.4)
R_{merge} (%) ^{1,2}	13.0 (67.0)
R_{meas} (%) ^{1,4}	15.4 (79.2)
R_{pim} (%) ^{1,4}	8.2 (41.8)
$CC_{1/2}$ ^{1,5}	0.994 (0.849)
Refinement	
Resolution (Å) ¹	42.00-2.20
Reflections (working/test) ¹	39,474/1,966
$R_{\text{factor}} / R_{\text{free}}$ (%) ^{1,3}	19.9/25.2
No. of atoms (Protein/Ligand/Water)	4,930/144/358
Model Quality	
R.m.s deviations	
Bond lengths (Å)	0.011
Bond angles (°)	1.144
Mean B -factor (Å) ²	
All Atoms	28.1
Protein	27.9
Ligand	26.0
Water	30.9
Coordinate error (maximum likelihood) (Å)	0.31
Ramachandran Plot	
Most favored (%)	97.3
Additionally allowed (%)	2.4

- 542
543
544
545
546
547
548
549
- 1) Values in parenthesis are for the highest resolution shell.
 - 2) $R_{\text{merge}} = \sum_{hkl} \sum_j |I_i(hkl) - \langle I(hkl) \rangle| / \sum_{hkl} \sum_i I_i(hkl)$, where $I_i(hkl)$ is the intensity measured for the i th reflection and $\langle I(hkl) \rangle$ is the average intensity of all reflections with indices hkl .
 - 3) $R_{\text{factor}} = \sum_{hkl} ||F_{\text{obs}}(hkl) - |F_{\text{calc}}(hkl)|| / \sum_{hkl} |F_{\text{obs}}(hkl)|$; R_{free} is calculated in an identical manner using 5% of randomly selected reflections that were not included in the refinement.
 - 4) R_{meas} = redundancy-independent (multiplicity-weighted) R_{merge} ^{38,45}. R_{pim} = precision-indicating (multiplicity-weighted) R_{merge} ^{46,47}
 - 5) $CC_{1/2}$ is the correlation coefficient of the mean intensities between two random half-sets of data^{48,49}

550 **FIGURE LEGENDS**

551 **Figure 1.** The SARS-CoV-2 Mac1 is a small domain within nsp3 and is highly conserved
552 between other human CoV Mac1 protein domains. **(A)** Cartoon Schematic of the SARS-CoV-2
553 non-structural protein 3. The conserved macrodomain, or Mac1, is highlighted in yellow. **(B)**
554 Sequence alignment of Mac1 from the highly-pathogenic human CoVs. Sequences were aligned
555 using the ClustalW method from Clustal Omega online tool with manual adjustment. Identical
556 residues are bolded, shaded in grey, and marked with asterisks.

557 **Figure 2.** Structure of SARS-CoV-2 Mac1 complexed with ADP-ribose. **A)** The structure was
558 rendered as a blend through model from the N-terminus (blue) to the C-terminus (red). **B)** The
559 structure was colored by secondary structure showing sheets (magenta) and helices (green). The
560 ADP-ribose is rendered as gray cylinders with oxygens and nitrogens colored red and blue,
561 respectively.

562 **Figure 3.** Binding mode of ADP-ribose in SARS-CoV-2 Mac1. **A)** Fo-Fc Polder omit map
563 (green mesh) contoured at 3σ . **B)** Hydrogen bond interactions (dashed lines) between ADP-
564 ribose and amino acids. **C)** Interactions with water molecules. Direct hydrogen bond interactions
565 are represented by dashed lines and water mediated contacts to amino acids are drawn as solid
566 lines.

567 **Figure 4.** Superposition of SARS-CoV-2 macrodomain (magenta) with coronavirus
568 macrodomain structures. **A)** SARS-CoV Mac1 with ADP-ribose (gold) (2FAV) and **B)** MERS-
569 CoV Mac1 with ADP-ribose (teal) (5HOL). Superposition of SARS-CoV-2 Mac1 (magenta) with
570 other coronavirus Mac1 structures highlighting the ADP-ribose binding site. **C)** SARS-CoV
571 (gold), **D)** MERS-CoV (teal). The ADP-ribose molecules are colored gray for SARS-CoV-2

572 Mac1 (**A-D**) and are rendered as green cylinders for SARS-CoV Mac1 (panel **A,C**) and MERS-
573 CoV Mac1 (panel **B,D**).

574 **Figure 5.** Human CoVs bind to ADP-ribose with similar affinity. **A-B**) ADP-ribose binding of
575 human Mdo2 and SARS-CoV, MERS-CoV, and SARS-CoV-2 Mac1 proteins by ITC. Images in
576 (**A**) are of one experiment representative of at least 2 independent experiments. Data in (**B**)
577 represent the combined averages of multiple independent experiments for each protein. Mdo2
578 n=2; SARS-CoV n=5; MERS-CoV n=6; SARS-CoV-2 n=2. **C**) ADP-ribose binding of
579 macrodomain proteins by DSF assay. Mdo2 n=4; SARS-CoV n=6; MERS-CoV n=5; SARS-
580 CoV-2 n=3.

581 **Figure 6.** SARS-CoV-2, SARS-CoV, and MERS-CoV Mac1 proteins are potent ADP-
582 ribosylhydrolases. **A,C**) The SARS-CoV-2 macrodomain (**A**) or multiple macrodomain proteins
583 (**C**) were incubated with MARYlated PARP10 CD *in vitro* for the indicated times at 37°C. ADP-
584 ribosylated PARP10 CD was detected by immunoblot (IB) with anti-mono ADP-ribose antibody
585 (Millipore-Sigma MAB1076). Total PARP10 CD and macrodomain protein levels were
586 determined by Coomassie Blue (CB) staining. PARP10 CD incubated alone at 37°C was stopped
587 at 0, 30 or 60 minutes. **B,D**) level of de-ADP-ribosylation was measured by quantifying band
588 intensity using Image J software. Intensity values were plotted and fit to a non-linear regression
589 curve (**B**) or as bar graphs representing the means with error bars representing standard deviation
590 (**D**). Results in **A** and **C** are representative experiments of two and three independent
591 experiments, respectively. Data in **B** and **D** represent the combined results of two and three
592 independent experiments, respectively. Asterisks indicate statistical significance between these
593 samples and the same timepoint from samples treated with Mdo2.

594

595 **SUPPLEMENTAL FIGURE LEGENDS**

596 **Figure S1.** Purification and crystallization of macrodomain proteins. **A)** Macrodomain proteins
597 were purified as described in Methods. Equimolar amounts of the recombinant proteins were run
598 on a polyacrylamide gel and visualized by Coomassie staining. **B)** Crystals of SARS-CoV-2
599 Mac1 obtained with Salt Rx HT E10 supplemented with 0.1 M NDSB-256.

600 **Figure S2.** Extended residues at the C-terminus of the SARS-CoV-2 Mac1 clashed with
601 symmetry related molecules. **A)** Comparison of the amino acid sequence of SARS-CoV-2 Mac1,
602 6W02 and 6WEY. **B)** Superposition of SARS-CoV-2 Mac1 (magenta) subunit B onto subunit A
603 of 6W02 reveals that the C-terminus would clash with symmetry related molecules (coral).

604 **Figure S3.** Superposition of SARS-CoV-2 Mac1 (magenta) with other recently determined
605 homologous structures. **A)** SARS-CoV-2 Mac1 apo structure (6WEN), **B)** SARS-CoV-2 Mac1
606 complexed with ADP-ribose (6W02). The ADP-ribose molecule is colored gray for SARS-CoV-2
607 and is represented as green cylinders for 6W02 in panel **B**. Comparison of the residues in the
608 ADP-ribose binding site. **C)** SARS-CoV-2 Mac1 apo structure (blue, 6WEN), **D)** SARS-CoV-2
609 Mac1 complexed with ADP-ribose (green, 6W02). The ADP-ribose of SARS-CoV-2 is rendered
610 as gray cylinders, and is represented as green cylinders for 6W02 in panel **B**.

611 **Figure S4.** Affinity of ADP-ribose binding antibodies for ADP-ribosylated PARP10 CD.
612 MARylated PARP10 and non-MARylated PARP10 CD were detected by immunoblot (IB) with
613 anti-GST (Invitrogen, MA4-004), anti-ADP-ribose antibodies: anti-MAR (Millipore-Sigma
614 MAB1076), anti-PAR (Millipore-Sigma MABC547), and anti-MAR/PAR (Millipore-Sigma
615 MABE1075) antibodies.




Figure 2. Structure of SARS-CoV-2 Mac1 complexed with ADP-ribose. **A)** The structure was rendered as a blend through model from the N-terminus (blue) to the C-terminus (red). **B)** The structure was colored by secondary structure showing sheets (magenta) and helices (green). The ADP-ribose is rendered as gray cylinders with oxygens and nitrogens colored red and blue, respectively.




Figure 3. Binding mode of ADP-ribose in SARS-CoV-2 Mac1. **A)** Fo-Fc Polder omit map (green mesh) contoured at 3σ . **B)** Hydrogen bond interactions (dashed lines) between ADP-ribose and amino acids. **C)** Interactions with water molecules. Direct hydrogen bond interactions are represented by dashed lines and water mediated contacts to amino acids are drawn as solid lines.





Figure 4. Superposition of SARS-CoV-2 macrodomain (magenta) with coronavirus macrodomain structures. **A)** SARS-CoV Mac1 with ADP-ribose (gold) (**2FAV**) and **B)** MERS-CoV Mac1 with ADP-ribose (teal) (**5HOL**). Superposition of SARS-CoV-2 Mac1 (magenta) with other coronavirus Mac1 structures highlighting the ADP-ribose binding site. **C)** SARS-CoV (gold), **D)** MERS-CoV (teal). The ADP-ribose molecules are colored gray for SARS-CoV-2 (A-D) and are rendered as green cylinders for SARS-CoV Mac1 (panel A,C) and MERS-CoV Mac1 (panel B,D).

A



B

Macrodomain	Stoichiometry (N)	Kd (µM)	ΔH (kcal/mol)	ΔG (kcal/mol)
Mdo2	0.92 ± 0.01	0.24 ± 0.02	-66 ± 1	-38 ± 2
SARS-CoV	0.89 ± 0.04	10.8 ± 1.7	-40 ± 1.2	-28 ± 0.4
MERS-CoV	0.97 ± 0.04	7.9 ± 0.15	-47 ± 3	-29 ± 0.4
SARS-CoV-2	1.14 ± 0.06	16.8 ± 0.04	-28 ± 0.1	-27 ± 0.1

C




Figure 5. Human CoVs bind to ADP-ribose with similar affinity. **A-B)** ADP-ribose binding of human Mdo2 and SARS-CoV, MERS-CoV, and SARS-CoV-2 Mac1 proteins by ITC. Images in **(A)** are of one experiment representative of at least 2 independent experiments. Data in **(B)** represent the combined averages of multiple independent experiments for each protein. Mdo2 n=2; SARS-CoV n=5; MERS-CoV n=6; SARS-CoV-2 n=2. **C)** ADP-ribose binding of macrodomain proteins by DSF assay. Mdo2 n=4; SARS-CoV n=6; MERS-CoV n=5; SARS-CoV-2 n=3.




Figure 6. SARS-CoV-2, SARS-CoV, and MERS-CoV Mac1 proteins are potent ADP-ribosylhydrolases. **A,C)** The SARS-CoV-2 macrodomain (**A**) or multiple macrodomain proteins (**C**) were incubated with MARylated PARP10 CD *in vitro* for the indicated times at 37°C. ADP-ribosylated PARP10 CD was detected by immunoblot (IB) with anti-ADP-ribose antibody (Millipore-Sigma MAB1076). Total PARP10 CD and macrodomain protein levels were determined by Coomassie Blue (CB) staining. PARP10 CD incubated alone at 37°C was stopped at 0, 30 or 60 minutes. **B,D)** level of de-ADP-ribosylation was measured by quantifying band intensity using Image J software. Intensity values were plotted and fit to a non-linear regression curve (**B**) or as bar graphs representing the means with error bars representing standard deviation (**D**). Results in **A** and **C** are representative experiments of two and three independent experiments, respectively. Data in **B** and **D** represent the combined results of two and three independent experiments, respectively. Asterisks indicate statistical significance between these samples and the same timepoint from samples treated with Mdo2.